台華新材(603055.SH):擬投12億元新設全資子公司 並以其為出資主體新設四家全資孫公司
格隆匯11月24日丨台華新材(603055.SH)公佈,根據公司的經營發展規劃及戰略佈局,公司準備在江蘇省淮安市洪澤區出資12億元設立全資子公司台華新材(江蘇)有限公司(“台華江蘇公司”),並以台華江蘇公司為出資主體新設四家全資孫公司,其中:
出資5億元設立全資孫公司嘉華再生尼龍(江蘇)有限公司,出資5億元設立全資孫公司嘉華特種尼龍(江蘇)有限公司,出資1億元設立全資孫公司台華織造(江蘇)有限公司,出資1億元設立全資孫公司台華染整(江蘇)有限公司。
本次新設子公司、孫公司後,將導致上市公司合併報表範圍發生變更,新設立的公司將被納入公司的合併報表範圍內。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.